A mismatched dosage unit or an off-brand adverse reaction term rarely stays a linguistic issue. It can delay marketing authorisation, trigger linguistic review comments that compress already tight timelines, or, in the worst cases, contribute to patient harm and product recalls. Across major markets the stakes sit higher than ordinary technical translation because labels, Summary of Product Characteristics (SmPC) documents, and package leaflets form part of the authorised product information itself.
In the European Union the Quality Review of Documents (QRD) templates set the structure, mandatory headings, and many fixed phrases for SmPCs, labelling, and patient leaflets. These templates exist in the official EU languages plus Icelandic and Norwegian. Standard statements cannot be freely paraphrased; each language version is expected to use the Agency-approved wording. Member State “blue-box” requirements and national preferences on decimals, number grouping, and certain abbreviations add further layers. Recent QRD style guidance has reinforced active voice for storage and handling instructions and cautioned against the standalone term “drug” because of mistranslation risks and unwanted connotations in several languages. Template updates must be applied across all language versions simultaneously; lagging versions generate findings during linguistic review.
MedDRA sits at the centre of the undesirable-effects section. Its hierarchical structure and stable numeric codes let the same clinical concept map consistently across languages and databases. Using an unofficial synonym, even one that sounds more natural, breaks that mapping and can obscure pharmacovigilance signals. Translators and reviewers therefore work from the official MedDRA release relevant to the submission rather than general medical dictionaries. Consistency across the SmPC, leaflet, and labelling is a review criterion, not a stylistic preference.
Outside Europe the picture shifts but the underlying discipline remains. FDA labelling follows its own structured formats under 21 CFR and the Physician Labeling Rule; English is the primary submission language, yet multilingual patient materials and non-English source data still require rigorous control. Japan, China, and many other markets impose their own templates, terminology expectations, and readability standards. Global programmes therefore need terminology management that survives jurisdictional differences while preserving the integrity of dosage, contraindications, interactions, and adverse-reaction information.
Real-world failures illustrate why process discipline matters. Studies of machine-generated or lightly reviewed Spanish prescription labels have found error rates around 50 percent in some pharmacy settings; the English word “once” left untranslated has been read as the number eleven, turning a once-daily instruction into an eleven-times-daily overdose risk. Broader analyses of FDA recall data have attributed roughly 15–19 percent of drug recalls in examined periods to labelling or packaging issues. Decimal separators, unit abbreviations (mg versus mcg), frequency expressions, and contraindications are recurring high-risk fields. These are not theoretical concerns—regulators treat incorrect product information as grounds for variation, suspension, or market withdrawal when patient safety is implicated.
Effective practice therefore combines several controls. Product-specific glossaries aligned with the current MedDRA version and the latest QRD decisions, version-controlled translation memories, dual linguistic and medical review, and systematic numerical validation of every dose, unit, and frequency statement catch many of the highest-risk errors. In-country or affiliate review supplies the final filter for national preferences and readability. Because QRD timelines after Day 180 leave limited room for rework, terminology and process decisions need to be locked early.
Pricing for multi-language pharmaceutical labelling reflects these realities more than raw word count. Factors include the number and rarity of target languages, the need for medical specialists and MedDRA-trained reviewers, formatting constraints on labels and leaflets, version-update cycles, and the cost of remediation if a submission is delayed. Rare language combinations and full QRD compliance packages naturally command higher rates than general medical text; the real cost comparison, however, is against the expense of a failed linguistic review or a safety-related variation.
Companies that treat pharmaceutical labelling translation as a specialised compliance activity rather than a bulk localisation task reduce both regulatory friction and patient risk. The same discipline that keeps MedDRA codes and QRD phrases intact also protects the integrity of the information patients and healthcare professionals ultimately rely on.
Artlangs Translation supports pharmaceutical and life-sciences clients with specialised regulatory translation and localisation across more than 230 languages. Drawing on more than 20 years of experience and a network of over 20,000 professional linguists, the company has delivered numerous complex projects in translation services, video localisation, short-drama subtitle localisation, game localisation, multilingual dubbing for short dramas and audiobooks, and multilingual data annotation and transcription.
